Targovax (NO: TRVX)

Last close As at 21/11/2024

9.07

0.00 (0.00%)

Market capitalisation

785m

Edison Investment Research is terminating coverage on Targovax. Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.

Previously published reports can still be accessed via our website.

Latest Insights

View More

Healthcare | Update

Targovax — Confirmatory 12-month mesothelioma update

Healthcare | Update

Targovax — ONCOS-102 plus durvalumab trial in spotlight

Healthcare | Update

Targovax — More data in 2020 from both clinical trials

Financials

Edison Investment Research is terminating coverage on Targovax. Please note you should no longer rely on any previous research or estimates for these companies. All forecasts should now be considered redundant.

Previously published reports can still be accessed via our website.

Update

Healthcare

Targovax — Key catalysts in 2018

Initiation

Healthcare

Targovax — Priming immune response in anticancer combos